WALTER V. KLEMP Company web. site http://www.moleculin.com
President, CEO and Chairman
Authorized Shares 100,000,000 as of 05/01.2020
Moleculin Announces Engagement with Voisin Consulting Life Sciences to Expand Annamycin Clinical Trial https://globenewswire.com/news-release/2018/05/03/1495957/0/en/Moleculin-Announces-Engagement-with-Voisin-Consulting-Life-Sciences-to-Expand-Annamycin-Clinical-Trial.html Outstanding Shares 60,403,164 as of 05/01/2020 Quarterly Report (10-q) May 11, 2020 https://ih.advfn.com/stock-market/NASDAQ/moleculin-biotech-MBRX/stock-news/82428874/quarterly-report-10-q Second Quarter Earnings 2019 https://ih.advfn.com/stock-market/NASDAQ/moleculin-biotech-MBRX/stock-news/80558492/moleculin-biotech-inc-reports-financial-results Moleculin Presentation May 31,2019 https://ir.moleculin.com/all-sec-filings Moleculin Announces First Patients Treated in European Annamycin Clinical Trial https://finance.yahoo.com/news/moleculin-announces-first-patients-treated-113000512.html Moleculin Announces the FDA has Granted Orphan Drug Designation for its Brain Tumor Drug https://www.otcmarkets.com/stock/MBRX/news/story?e&id=1276755 Moleculin Announces Significant Milestone Achieved in Glioblastoma Trial
https://ih.advfn.com/p.php?pid=nmona&article=78590137&symbol=MBRX Moleculin Announces Positive Data on WP1066 in Pre-Clinical Trials
https://ih.advfn.com/p.php?pid=nmona&article=78537668&symbol=MBRX Moleculin Announces New Data Discovery Confirming Significant Increase in Potential to Starve Cancerous Tumors https://ih.advfn.com/p.php?pid=nmona&article=78433601&symbol=MBRX Moleculin receives approval for leukemia clinical trial; shares ahead 23% premarket
https://seekingalpha.com/news/3365150-moleculin-receives-approval-leukemia-clinical-trial-shares-ahead-23-percent-premarket Moleculin Targets accelerated FDA approval of WP1732; Pursues Development for Ocular Tumors
Moleculin Enters Agreement with Seidman Cancer Center to Conduct Leukemia Clinical Trials Moleculin Announces Grant-Funded Collaboration to Expand Understanding of New Discovery http://www.marketwired.com/press-release/moleculin-announces-grant-funded-collaboration-expand-understanding-new-discovery-2246407.htm
Moleculin Biotech, Inc. (Nasdaq: MBRX) to Ring The Nasdaq Stock Market Closing Bell in celebration of IPO
Metabasis Therapeutics (NASDAQ:MBRX)
Historical Stock Chart
Moleculin Biotech (Nasdaq:MBRX), a preclinical and clinical-stage pharmaceutical company focused on the development of anti-cancer drug candidates, will visit the Nasdaq MarketSite in Times Square to celebrate its initial public offering (IPO).
In honor of the occasion, Walter Klemp, Chief Executive Officer, will ring the Closing Bell.
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
Thursday, June 2, 2016 – 3:45 p.m. to 4:00 p.m. ET
Moleculin Biotech Media Contact: